CSTL250117P22500
- 0.25
- 0.000.00%
Castle Biosciences Newsroom
4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now
Leerink Partners Maintains Castle Biosciences(CSTL.US) With Buy Rating, Announces Target Price $50
Castle Biosciences to Share Data on DecisionDx-SCC
Castle's Poster on DecisionDx-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
Insider Sale: Pres. & Chief Exec. Officer of $CSTL (CSTL) Sells 192 Shares
Castle Biosciences Stock Tumbles Following Guidance Concerns
Express News | Castle Biosciences Shares Are Trading Lower After the Company Reported Preliminary FY24 Financial Results
Castle Biosciences | 8-K: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments
Castle Biosciences Positioned for Growth After Novitas Resolution and Focus on Core Franchises
Express News | Castle Biosciences Inc - 2024 Revenue Expected to Exceed $320-330 Million, 50% Growth Over 2023
Press Release: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
Castle Biosciences Drops as Regional Medicare Contractor Won't Cover Test
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $40
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $44
Canaccord Genuity Keeps Their Buy Rating on Castle Biosciences (CSTL)
Insider Sale: Director at $CSTL (CSTL) Sells 434 Shares
Sector Update: Health Care Stocks Rise in Afternoon Trading
Rock Star Growth Puts Castle Biosciences (NASDAQ:CSTL) In A Position To Use Debt